Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Artiva Biotherapeutics (ARTV) Total Liabilities (2023 - 2025)

Artiva Biotherapeutics (ARTV) has disclosed Total Liabilities for 3 consecutive years, with $21.0 million as the latest value for Q4 2025.

  • Quarterly Total Liabilities fell 8.59% to $21.0 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $21.0 million through Dec 2025, down 8.59% year-over-year, with the annual reading at $21.0 million for FY2025, 8.59% down from the prior year.
  • Total Liabilities for Q4 2025 was $21.0 million at Artiva Biotherapeutics, up from $19.6 million in the prior quarter.
  • The five-year high for Total Liabilities was $174.7 million in Q1 2024, with the low at $19.6 million in Q3 2025.
  • Average Total Liabilities over 3 years is $65.7 million, with a median of $24.6 million recorded in 2024.
  • Peak annual rise in Total Liabilities hit 8.59% in 2025, while the deepest fall reached 87.13% in 2025.
  • Over 3 years, Total Liabilities stood at $50.7 million in 2023, then crashed by 54.77% to $22.9 million in 2024, then decreased by 8.59% to $21.0 million in 2025.
  • According to Business Quant data, Total Liabilities over the past three periods came in at $21.0 million, $19.6 million, and $20.3 million for Q4 2025, Q3 2025, and Q2 2025 respectively.